Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22508376 | 1.00 | DRD2 (0.32) | DRD2DRD3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL24489496 | 0.90 | — | — | |
| SCHEMBL10444250 | 0.89 | — | — | |
| SCHEMBL10444356 | 0.89 | — | — | |
| SCHEMBL10444310 | 0.86 | — | — | |
| SCHEMBL10444634 | 0.86 | KDM4E (0.31) | — | |
| SCHEMBL10446513 | 0.86 | EEF2K (0.31) | — | |
| SCHEMBL10444631 | 0.84 | HTR2A (0.38) | DRD2DRD3 | |
| SCHEMBL10444593 | 0.84 | ALDH1A1 (0.34) | DRD2DRD3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL20101879 | 0.84 | ALDH1A1 (0.34) | DRD2DRD3CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177487-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2020205835-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020205832-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177487-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | PDXK, PNPO, CDKN1A | DRD2 4744/4885DRD3 4803/4885CHRNB2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.